Cabio Biotech (Wuhan) Co., Ltd.

Shanghai Stock Exchange 688089.SS

Cabio Biotech (Wuhan) Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2023: USD 33.76 M

Cabio Biotech (Wuhan) Co., Ltd. Cash and Short-Term Investments is USD 33.76 M for the year ending December 31, 2023, a -55.80% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Cabio Biotech (Wuhan) Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 76.39 M, a -28.20% change year over year.
Cabio Biotech (Wuhan) Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 106.38 M, a -19.33% change year over year.
Cabio Biotech (Wuhan) Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 131.88 M, a 8.77% change year over year.
Cabio Biotech (Wuhan) Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 121.24 M, a 582.89% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Shanghai Stock Exchange: 688089.SS

Cabio Biotech (Wuhan) Co., Ltd.

CEO	Mr. Dewei Yi
IPO Date	Dec. 19, 2019
Location	China
Headquarters	No. 999 high-tech Avenue
Employees	508
Sector	Consumers Staples
Industries Pet Food Baby & Childcare Consumer Packaged Goods Cosmetics Dairy & Milk Food & Beverages Personal Care Pharmaceuticals

Description

Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. Its products are used in infant formula food, health food, dietary supplements, and other fields for special medical purposes, pet nutrition food, economic animal feed, personal care and cosmetics, and other fields. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.

Key trends

Past 5 years